Linking Gut-Microbiota Biomarkers with Improved Clinical Response in Alzheimer’s Patients Treated with ANAVEX2-73
Date & Time
Thursday, June 4, 2020, 12:40 PM - 1:05 PM
Christopher Missling

• Discover the correlations between the gut microbiota and response to the drug in Alzheimer’s patients.

• Assess the mechanism of action of the drug from 2020 phase 2b/3 clinical data from 450 Alzheimer’s patients.

• Analyze the genomic biomarkers used in the study to determine efficacy and apply to your own discovery pipeline.

• Understand how and why the high levels of two specific microbial families improve ANAVEX2-73 response in Alzheimer’s patients.

Session Type
Virtual Session Link
Session Themes
On Demand